Selected arylsulphonyl pyrazole derivatives as potential Chk1 kinase ligands-computational investigations

Kornelia Czaja1, Jacek Kujawski2, Karol Kamel3

  • 1Chair and Department of Organic Chemistry, Faculty of Pharmacy, Poznan University of Medical Sciences, ul. Grunwaldzka 6, 60-780, Poznan, Poland. czaja.kornelia@gmail.com.

Insights

This study investigated how arylsulphonyl pyrazole and indazole derivatives interact with Checkpoint 1 kinase (Chk1). Indazole derivative 4 and pyrazoloquinoline derivative 7 show promising binding affinity for Chk1, suggesting potential anticancer applications.

Area of Science:

  • Biochemistry and Medicinal Chemistry
  • Molecular Biology
  • Computational Chemistry

Background:

  • Protein kinases, like Checkpoint 1 kinase (Chk1), are crucial for DNA repair and cancer cell survival.
  • Chk1 is a significant target for developing novel anticancer agents.
  • Previous research indicated anticancer effects of certain arylsulphonyl indazole derivatives in vitro.

Purpose of the Study:

  • To explore the potential interactions between pyrazole and indazole derivatives and the Chk1 kinase.
  • To identify specific derivatives with high binding affinity to the Chk1 active site for anticancer drug development.

Main Methods:

  • Molecular docking of tosyl derivatives of indazole and condensed pyrazole to the Chk1 kinase pocket.
  • Density Functional Theory (DFT) formalism for analyzing ligand-protein interactions.
  • PM7 method for estimating interaction enthalpy and molecular dynamics for ligand relaxation and hydrogen bond analysis.

Main Results:

  • Indazole derivative 4 (5-substituted with 3,5-dimethylpyrazole) and pyrazoloquinoline derivative 7 exhibited the strongest binding to the Chk1 pocket.
  • Calculated interaction enthalpy (ΔHint) values ranged from -85.06 to -124.04 kcal mol-1.
  • Analysis revealed specific hydrogen contacts and ligand relaxation within the Chk1-binding site.

Conclusions:

  • Arylsulphonyl indazole and pyrazole derivatives show significant potential as Chk1 inhibitors.
  • Derivatives 4 and 7 are identified as lead compounds for further development as anticancer therapeutics targeting Chk1.
  • Computational methods provide valuable insights into ligand-protein interactions for drug design.

Related Concept Videos